Across TCGA pan-cancer cohorts, POLR3C Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated POLR3C data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher POLR3C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated POLR3C expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, GBM, and COAD are the cancer types where POLR3C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.027	0.963	<.001	36	view →
GBM	DFS	Median	All	0.043	0.257	<.001	12	view →
COAD	OS	Median	All	0.168	0.806	.002	12	view →
UCEC	DFS	Median	All	1.000	0.630	.036	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: POLR3C tumor-vs-normal RNA expression · all POLR3C data types